Metabolism/transport effects substrate of CYP2C9 (minor). Note: Assignment of major/minor substrate status based on clinically relevant drug interaction potential. Inhibits CYP2C8 (moderate), CYP2D6 (weak), CYP3A4 (weak).
Pimozide: Avoid concomitant use.
ACE inhibitors, amifostine, antihypertensives, aripiprazole, carvedilol, cyclosporine (systemic), CYP2C8 substrates, CYP2C9 substrates, hypotensive agents, lithium, lomitapide, non-steroidal anti-inflammatory agents, pimozide, potassium-sparing diuretics, rituximab, sodium phosphates: Increased levels/effect/toxicity with irbesartan.
Alfuzosin, aliskiren, diazoxide, eplerenone, fluconazole, herbs (hypotensive properties), MAO inhibitors, pentoxyfylline, phosphodiesterase-5 inhibitors, potassium salts, prostacyclin analogues, tolvaptan, trimethoprim: Increased levels/effect of irbesartan.
Herbs (hypertensive properties), methylphenidate, non-steroidal anti-inflammatory agents, rifamycin derivatives, yohimbine: Decreased effect of irbesartan.
Ethanol/Nutrition/Herb Interactions: Herb/Nutraceutical: Dong quai has estrogenic activity. Some herbal medications may worsen hypertension (eg, ephedra). Garlic may have additional antihypertensive effects. Management: Avoid dong quai if using for hypertension. Avoid ephedra, yohimbine, ginseng and garlic.